HHS awards Eigen two grants from Qualifying Therapeutic Discovery Project

Eigen is the proud recipient of two grant awards from the Qualifying Therapeutic Discovery Project (QTDP) funded by the U.S. Department of Health & Human Services. QTDP tax credits are provided under section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). Eigen received the maximum $244,000 award for each grant awarded in October, 2010, and January, 2011. These credits support biomedical research by small companies which may have major impact on the diagnosis and treatment of significant diseases.  

With this grant, Eigen continues to rapidly move forward, bringing breakthrough medical imaging products to market. Additionally, the QTDP grants have enabled the company to hire additional local talent to support growing company needs.  

Artemis, Eigen's flagship product, uses proprietary, next-generation imaging technology and provides solutions—not previously available—which enhance urologists' existing 2D ultrasound imagery with full color 3D modeling used for "smart" prostate biopsies.

"Artemis has provided a great leap forward in the diagnosis of prostate cancer," says Brian Burr, Eigen CEO. "It has added precision along with the ability to guide, track, and record exact biopsy locations. Artemis lets doctors re-biopsy the same location accurately in a subsequent biopsy. This has previously not been an option. Artemis technology provides high quality, real-time information that enhances how prostate cancer is managed. Better patient information equals better patient decisions."

Eigen is also breaking into the prostate cancer therapy market.  The company hopes to receive future support from such programs as the QTDP, allowing it to continue providing quality imaging devices to medical professionals worldwide.